Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Pilcher

Cardiovascular Disease Jacksonville, FL Medical Doctor

NPI 1306849583 CMS profile 149542

1824 King Street, Suite 300, Jacksonville, FL 32204

Open in the dashboard

General payments

$17,732

268 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Pilcher of Jacksonville, FL is reported in the CMS Open Payments database as having received $17,732 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,325 20
2024 General $4,109 30
2023 General $2,398 51
2022 General $2,714 39
2021 General $2,547 41
2020 General $1,973 35
2019 General $2,665 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Pilcher
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to George Pilcher were reported at $1,325. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year George Pilcher Cardiovascular Disease median Middle half National median
2019 $2,665 $450 $127–$1,392 $163
2020 $1,973 $242 $77–$751 $114
2021 $2,547 $335 $101–$1,037 $132
2022 $2,714 $395 $121–$1,211 $149
2023 $2,398 $443 $136–$1,283 $160
2024 $4,109 $450 $136–$1,323 $164
2025 $1,325 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $13,216 161 payments
  2. Inari Medical, Inc. $1,030 14 payments
  3. Abbott Laboratories $925 14 payments
  4. Edwards Lifesciences Corporation $686 7 payments
  5. Shockwave Medical, Inc $620 31 payments
  6. ZOLL Circulation Inc $339 11 payments
  7. HeartFlow, Inc. $172 2 payments
  8. Medtronic, Inc. $134 1 payment
  9. Janssen Pharmaceuticals, Inc $109 4 payments
  10. Recor Medical Inc $106 1 payment
  11. Other $394 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,032 267 payments
  2. Honoraria $2,700 1 payment
Products named General payments · program years 2019–2025
  1. Impella $12,250 146 payments
  2. CT THROMBECTOMY SYSTEM KIT $903 8 payments
  3. FLOWTRIEVER CATHETER, S $903 8 payments
  4. Mitra Clip system $566 7 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $371 26 payments
  6. Edwards SAPIEN 3 Transcatheter Heart Valve $340 3 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $224 3 payments
  8. Temperature Management System Start-Up Kit $210 8 payments
  9. Catheter $210 8 payments
  10. Temperature Management System $210 8 payments
  11. Other $2,146 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

3,212

Median for Cardiology: 2,533

Drug cost

$524,972

Median for Cardiology: $485,213

Branded share of claims

31.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 168 $200,717
Eliquis Apixaban Brand 123 $136,071
Repatha Sureclick Evolocumab Brand 83 $79,177
Jardiance Empagliflozin Brand 29 $32,676
Xarelto Rivaroxaban Brand 39 $31,684
Praluent Pen Alirocumab Brand 15 $10,942
Atorvastatin Calcium Generic 456 $4,823
Clopidogrel Clopidogrel Bisulfate Brand 285 $3,396
Nebivolol Hcl Generic 63 $2,788
Ezetimibe Generic 143 $2,763

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$169,938

Medicare's payments for the services billed

Medicare patients

913

Average age 76

Services billed

1,761

398 women, 515 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Arthritis 53%
Diabetes 45%
Heart failure 41%
Chronic kidney disease 40%
Atrial fibrillation 38%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record